article thumbnail

Trends in the Clinical Characteristics and Outcome of Infective Endocarditis: A Nationwide Study From 2016 to 2021

Journal of the American Heart Association

This study sought to examine temporal trends in the clinical characteristics and inhospital occurrence of adverse outcomes of IE.Methods and ResultsUsing the Japan nationwide administrative database, we identified patients with IE in Japan from 2016 to 2021. per 100 000 population in 2016 to 2.59 in 2016 to 15.4%

article thumbnail

Predicting the risk of heart failure after acute myocardial infarction using an interpretable machine learning model

Frontiers in Cardiovascular Medicine

Background Early prediction of heart failure (HF) after acute myocardial infarction (AMI) is essential for personalized treatment. The primary endpoint was the occurrence of HF within 3 years after operation.

article thumbnail

AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure

DAIC

Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2 Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2

article thumbnail

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

DAIC

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heart failure (CHF). Heart failure. 2016:25:2. [5]

article thumbnail

Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction

The New England Journal of Medicine

Treatment options for heart failure with preserved ejection fraction have historically been limited. In a 2016 review of this condition in the Journal, treatment recommendations focused on diuretics, exercise training, and management of coexisting conditions.1

article thumbnail

Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease

Cardiovascular Diabetology

Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. The use of cardioprotective GLD increased rapidly in recent years (2016–2021; 7–47%) and was more common in younger patients (66 vs. 68 years) and men (72.9%

article thumbnail

Use of natriuretic peptides and echocardiography for diagnosing heart failure

European Journal of Heart Failure

Diagrammatic illustration of trends of incident heart failure diagnosis and diagnostic testing in the US from 2016 to 2019 stratified by inpatient and outpatient setting. However, real-world utilization of these diagnostic tests in the US is not known.